FDA Approves Ropeginterferon Alfa-2b-njft (Besremi) Treatment for Rare Blood Disease Polycythemia Vera (PV).
SUMMARY: PharmaEssentia Corporation a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in…